MX2020003126A - Derivados de iminopirimidina ciclicos como inhibidores de cinasa. - Google Patents

Derivados de iminopirimidina ciclicos como inhibidores de cinasa.

Info

Publication number
MX2020003126A
MX2020003126A MX2020003126A MX2020003126A MX2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A
Authority
MX
Mexico
Prior art keywords
cyclic
derivatives
iminopyrimidine
kinase inhibitors
compounds
Prior art date
Application number
MX2020003126A
Other languages
English (en)
Spanish (es)
Inventor
Chen Chen
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of MX2020003126A publication Critical patent/MX2020003126A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2020003126A 2017-09-20 2018-09-20 Derivados de iminopirimidina ciclicos como inhibidores de cinasa. MX2020003126A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561142P 2017-09-20 2017-09-20
PCT/US2018/052047 WO2019060611A1 (en) 2017-09-20 2018-09-20 CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES

Publications (1)

Publication Number Publication Date
MX2020003126A true MX2020003126A (es) 2020-10-01

Family

ID=64457074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003126A MX2020003126A (es) 2017-09-20 2018-09-20 Derivados de iminopirimidina ciclicos como inhibidores de cinasa.

Country Status (9)

Country Link
US (2) US11254680B2 (https=)
EP (1) EP3684772B1 (https=)
JP (1) JP7394768B2 (https=)
KR (1) KR102796209B1 (https=)
CN (1) CN111247152B (https=)
AU (1) AU2018338098B2 (https=)
CA (1) CA3076202A1 (https=)
MX (1) MX2020003126A (https=)
WO (1) WO2019060611A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
PH12022551118A1 (en) * 2019-12-10 2023-09-18 Hoffmann La Roche New braf inhibitors as paradox breakers
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
CA3179671A1 (en) * 2020-08-07 2022-02-10 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
CN114380697A (zh) * 2021-11-30 2022-04-22 上海毕得医药科技股份有限公司 一种n-甲基乙基胺盐酸盐的制备工艺
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN117209503B (zh) * 2023-09-13 2025-10-17 苏州翔实医药发展有限公司 一种5,6-二氢咪唑并[1,2-c]喹唑啉及其衍生物合成的方法
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含braf抑制劑的藥物組合物及其在醫藥上的應用
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82205C2 (en) * 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US20100216779A1 (en) 2007-06-01 2010-08-26 Glaxosmithkline Llc Imidazopyridine Kinase Inhibitors
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
PL2647637T3 (pl) * 2010-12-02 2016-06-30 Medpacto Inc Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
CN104703599A (zh) * 2012-09-14 2015-06-10 永恒生物科技公司 作为蛋白激酶抑制剂的氨基异喹啉衍生物
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9321762B2 (en) 2013-12-11 2016-04-26 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
CN105272970A (zh) 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途
MX385110B (es) * 2014-07-16 2025-03-11 Dev Ct Biotechnology Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos.
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors

Also Published As

Publication number Publication date
JP7394768B2 (ja) 2023-12-08
US11932647B2 (en) 2024-03-19
EP3684772B1 (en) 2023-12-06
RU2020113707A (ru) 2021-10-20
JP2020534373A (ja) 2020-11-26
RU2020113707A3 (https=) 2021-12-23
US20220251089A1 (en) 2022-08-11
CN111247152A (zh) 2020-06-05
EP3684772C0 (en) 2023-12-06
CN111247152B (zh) 2024-07-16
KR20200055034A (ko) 2020-05-20
BR112020005455A2 (pt) 2020-09-24
AU2018338098A1 (en) 2020-05-07
CA3076202A1 (en) 2019-03-28
AU2018338098B2 (en) 2024-02-22
EP3684772A1 (en) 2020-07-29
WO2019060611A1 (en) 2019-03-28
KR102796209B1 (ko) 2025-04-16
US20200247813A1 (en) 2020-08-06
US11254680B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
ZA202401324B (en) Tyrosine kinase inhibitors
ZA202405294B (en) Heterocyclic compounds as immunomodulators
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
MX391720B (es) Terapia combinada para tratar cáncer.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
AU2018380132A8 (en) Tubulin inhibitors
MX2016014436A (es) Derivados de heterociclil-butanamida.
EA201790603A1 (ru) Ингибиторы гистондеметилазы
JOP20170108A1 (ar) مثبطات معزز نظير zeste 2
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2016008042A (es) Derivados de imidazopirazinona.
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы